Digging into the Data: Understanding the Benefits of Ovarian Suppression for Young Women
New findings from the Suppression of Ovarian Function Trial (SOFT) found that adding ovarian suppression to adjuvant exemestane (Aromasin) or to tamoxifen significantly reduced a premenopausal woman’s risk for recurrence. Join LBBC’s Young Women’s Initiative and Dana-Farber Cancer Institute’s Ann Partridge, MD, MPH, to hear more about these findings and what it means for you.
During this webinar you:
- Learned more about the implications of these trial results and how it may impact your care
- Learned about the side effects and quality of life impacts of ovarian suppression and how to manage these impacts
- Heard from young women affected by breast cancer about their experience with ovarian suppression
- Explored what questions to ask your doctor and concerns you need to consider when making your treatment decisions around ovarian suppression
About Our Speaker:
Ann Partridge, MD, MPH, is a medical oncologist and clinical researcher in the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, focused on improving the care and outcomes of patients with cancer, with a particular focus on breast cancer. She is the former clinical director of the breast oncology program, founded and directs the program for young women with breast cancer, and was recently named the director of the adult survivorship program at Dana-Farber/Brigham and Women’s Cancer Center.